Onkologie. 2016:10(2):92-97 | DOI: 10.36290/xon.2016.021

Neuromuscular symptomatology as primary manifestation of a malignant neoplasm and a phylogenetic importance

Jana Neuwirthová, Břetislav Gál, Pavel Smilek, Hana Binková, Pavla Urbánková, Rom Kostřica
Klinika otorinolaryngologie a chirurgie hlavy a krku, FN u sv. Anny v Brně

of behaviour changes induced by proinflamatory cytokines

Pro-inflammatory cytokines and hormonal changes in oncological diseases induce metabolic, neurological and psychic changes

which could be presented as first symptoms of an occult malignant neoplasm. Moreover, the production of several types of auto-

antibodies could make symptoms similar to autoimmune diseases. Specific behaviour changes due to pro-inflammatory signals

from the periphery are characteristic for all mammals and have their own phylogenetic importance, which have been developed

with wounded and sick animals in order to redistribute their energy resources to facilitate healing wounds and infections on the

one hand, and to induce hyper-vigilance against a future predator attack on the other hand.

Keywords: paraneoplastic symptom, sickness behaviour, pro-inflammatory cytokine, myalgia, insomnia, depression

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Neuwirthová J, Gál B, Smilek P, Binková H, Urbánková P, Kostřica R. Neuromuscular symptomatology as primary manifestation of a malignant neoplasm and a phylogenetic importance. Onkologie. 2016;10(2):92-97. doi: 10.36290/xon.2016.021.
Download citation

References

  1. Pyter LM, Pineros V, Galang JA, et al. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A 2009; 106(22): 9069-9074. Go to original source... Go to PubMed...
  2. Lamkin DM, Lutgendorf SK, Lubaroff D, et al. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav Immun 2011; 25(3): 555-564. Go to original source... Go to PubMed...
  3. Lutgendorf SK, Weinrib AZ, Penedo F, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008; 26(29): 4820-4827. Go to original source... Go to PubMed...
  4. Capuron L, Fornwalt FB, Knight BT, et al. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 2009; 119(1-3): 181-185. Go to original source... Go to PubMed...
  5. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4(11): 686-694. Go to original source... Go to PubMed...
  6. Owusu-Apenten R. Proinflammatory signaling. In: Bioactive peptides. Applications for Improving Nutrition and Health. New York CRC Press 2010: 188-197. Go to original source...
  7. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012; 32(4): 1119-1136.
  8. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006, 119(2): 254-264. Go to original source... Go to PubMed...
  9. Suzuki S. Lambert-Eaton myasthenic syndrome (LEMS). Brain Nerve 2010; 62(4): 419-426. Go to PubMed...
  10. Mehta SH, Morgan JC, Sethi KD. Paraneoplastic movement disorders. Curr Neurol Neurosci Rep. 2009; 9(4): 285-291. Go to original source... Go to PubMed...
  11. Ogawa E, Sakakibara R, Kawashima K, et al. VGCC antibody-positive paraneoplastic cerebellardegeneration presenting with positioning vertigo. Neurol Sci 2011, 32(6): 1209-1212. Go to original source... Go to PubMed...
  12. Vitkovic Konsman J, Bockaert J, et al. Cytokine signals propagate through the brain. Mol Psychiatry 2000, 5: 604-615. Go to original source... Go to PubMed...
  13. Bluthe RM, Walter V, Parnet P, et al. Lipopolysacchride induces sickness behavior in rats by a vagal mediated mechanism. C R Acad Sci III 1994; 317: 499-503.
  14. Banks WA, Kastin AJ. Blood to brain transport of interleukin links the immune and central nervous system. Life Sci 1991; 48: PL117-121. Go to original source... Go to PubMed...
  15. Romeo HE, Tio DL, Rahman SU, et al. The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 2001; 115(1-2): 91-100. Go to original source... Go to PubMed...
  16. Blaylock RL. Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity. Surg Neurol Int. 2013; 4: 118. Go to original source... Go to PubMed...
  17. Escudero GE, Roma?uk CB, Toledo ME, Olivera ME, Manzo RH, Laino CH. Analgesia enhancement and prevention of tolerance to morphine: beneficial effects of combined therapy with omega-3 fatty acids. J Pharm Pharmacol. 2015 May 25. doi: 10.1111/jphp.12416. Go to original source... Go to PubMed...
  18. O'Connor JC, Lawson MA, André C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009; 14(5): 511-522. Go to original source... Go to PubMed...
  19. Wu HQ, Rassoulpour A, Schwarcz R. Kynurenic acid leads, dopamine follows: new case of volume transmission in the brain? J Neural Transm. 2007; 114(1): 33-41. Go to original source... Go to PubMed...
  20. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002; 303(1): 1-10. Go to original source... Go to PubMed...
  21. Brydon L, Harrison NA, Walker C, et al. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008; 63(11): 1022-1029. Go to original source... Go to PubMed...
  22. Eisenberger NI, Berkman ET, Inagaki TK, et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010, 68(8): 748-754. Go to original source... Go to PubMed...
  23. Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008; 26(6): 971-982. Go to original source... Go to PubMed...
  24. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012, 33(3): 315-327. Go to original source... Go to PubMed...
  25. Breitbart W, Alici Y. Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs 2008; 12(5Suppl): 27-36. Go to original source... Go to PubMed...
  26. Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008; 23(1): CD006704. Go to original source... Go to PubMed...
  27. Breitbart W, Alici Y. Psychostimulants for cancer-related fatigue. J Natl Compr Canc Netw 2010; 8(8): 933-942. Go to original source... Go to PubMed...
  28. Montana MC, Gereau RW. Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation. Curr Pharm Biotechnol 2011; 12(10):1681-8. Go to original source... Go to PubMed...
  29. Ader R. Behavior and immunity. In: Ader R. Psychoneuroimmunology, Vol. 2, New York Academic Press, 2007: 524.
  30. Cannon W. The wisdom of the body. New York Norton Pubs: 1932. Go to original source...
  31. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res. 2008; 14(2-3): 169-183. Go to original source... Go to PubMed...
  32. Eisenberger NI, Berkman ET, Inagaki TK, et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010; 68(8): 748-754. Go to original source... Go to PubMed...
  33. Lampa J, Westman M, Kadetoff D, et al. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc Natl Acad Sci USA 2012; 109(31): 12728-12733. Go to original source... Go to PubMed...
  34. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012; 33(3): 315-327. Go to original source... Go to PubMed...
  35. Hart BL. The behavior of sick animals. Vet Clin North Am Small Anim Pract 1991; 21(2): 225-237. Go to original source... Go to PubMed...
  36. Andrew H. Miller, William P. Timmie. Mechanisms of Cytokine-Induced Behavioral Changes: Psychoneuroimmunology at the Translational Interface Norman Cousins Lecture. Brain Behav Immun 2009; 23(2): 149-158. Go to original source... Go to PubMed...
  37. Capuron L, Pagnoni G, Demetrashvili M, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 2005; 58(3): 190-196. Go to original source... Go to PubMed...
  38. Braver TS, Barch DM, Gray JR, et al. Anterior cingulate cortex and response conflict: effects of frequency, inhibition and errors. Cereb Cortex 2001; 11(9): 825-836. Go to original source... Go to PubMed...
  39. Eisenberger NI, Lieberman MD. Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn Sci 2004; 8(7): 294-300. Go to original source... Go to PubMed...
  40. Mavrogiorgou P, Juckel G. Interferon-induced obsessive-compulsive symptoms in malignant melanoma. Pharmacopsychiatry 2012; 45(1): 28-30. Go to original source... Go to PubMed...
  41. Opp MR. Cytokines and sleep. Sleep Med Rev 2005; 9(5): 355-64. Go to original source... Go to PubMed...
  42. Raison CL, Rye DB, Woolwine BJ, et al. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry 2010; 68(10): 942-949. Go to original source... Go to PubMed...
  43. Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001; 10(4): 245-255. Go to original source... Go to PubMed...
  44. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004, 89(5): 2119-2126. Go to original source... Go to PubMed...
  45. Irwin MR, Wang M, Campomayor CO, et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006; 66(16): 1756-1762. Go to original source... Go to PubMed...
  46. Basta M, Chrousos GP, Vela-Bueno A, Vgontzas AN. Chronic insomnia and stress system. Sleep Med Clin 2007; 2(2): 279-291. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.